293 related articles for article (PubMed ID: 32639068)
21. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
[TBL] [Abstract][Full Text] [Related]
22. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
[TBL] [Abstract][Full Text] [Related]
23. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
24. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
Zhang N; Wei L; Ye M; Kang C; You H
Front Immunol; 2020; 11():592612. PubMed ID: 33329578
[TBL] [Abstract][Full Text] [Related]
25. Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape.
Mohme M; Maire CL; Schliffke S; Joosse SA; Alawi M; Matschke J; Schüller U; Dierlamm J; Martens T; Pantel K; Riethdorf S; Lamszus K; Westphal M
Acta Neuropathol Commun; 2020 Mar; 8(1):28. PubMed ID: 32151286
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma.
Lee AH; Sun L; Mochizuki AY; Reynoso JG; Orpilla J; Chow F; Kienzler JC; Everson RG; Nathanson DA; Bensinger SJ; Liau LM; Cloughesy T; Hugo W; Prins RM
Nat Commun; 2021 Nov; 12(1):6938. PubMed ID: 34836966
[TBL] [Abstract][Full Text] [Related]
28. Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma.
Ye Z; Ai X; Yang K; Yang Z; Fei F; Liao X; Qiu Z; Gimple RC; Yuan H; Huang H; Gong Y; Xiao C; Yue J; Huang L; Saulnier O; Wang W; Zhang P; Dai L; Wang X; Wang X; Ahn YH; You C; Xu J; Wan X; Taylor MD; Zhao L; Rich JN; Zhou S
Cancer Discov; 2023 Apr; 13(4):974-1001. PubMed ID: 36649564
[TBL] [Abstract][Full Text] [Related]
29. Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade.
Nair S; Mazzoccoli L; Jash A; Govero J; Bais SS; Hu T; Fontes-Garfias CR; Shan C; Okada H; Shresta S; Rich JN; Shi PY; Diamond MS; Chheda MG
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33232299
[TBL] [Abstract][Full Text] [Related]
30. Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma.
Yeo AT; Charest A
J Cell Biochem; 2017 Sep; 118(9):2516-2527. PubMed ID: 28230277
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 expression and prognostic impact in glioblastoma.
Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
[TBL] [Abstract][Full Text] [Related]
32. Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Schmid RS; Simon JM; Vitucci M; McNeill RS; Bash RE; Werneke AM; Huey L; White KK; Ewend MG; Wu J; Miller CR
Neuro Oncol; 2016 Jul; 18(7):962-73. PubMed ID: 26826202
[TBL] [Abstract][Full Text] [Related]
33. Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas.
Arrieta VA; Gould A; Kim KS; Habashy KJ; Dmello C; Vázquez-Cervantes GI; Palacín-Aliana I; McManus G; Amidei C; Gomez C; Dhiantravan S; Chen L; Zhang DY; Saganty R; Cholak ME; Pandey S; McCord M; McCortney K; Castro B; Ward R; Muzzio M; Bouchoux G; Desseaux C; Canney M; Carpentier A; Zhang B; Miska JM; Lesniak MS; Horbinski CM; Lukas RV; Stupp R; Lee-Chang C; Sonabend AM
Nat Commun; 2024 Jun; 15(1):4698. PubMed ID: 38844770
[TBL] [Abstract][Full Text] [Related]
34. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
[TBL] [Abstract][Full Text] [Related]
35. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for glioblastoma: the promise of combination strategies.
Bausart M; Préat V; Malfanti A
J Exp Clin Cancer Res; 2022 Jan; 41(1):35. PubMed ID: 35078492
[TBL] [Abstract][Full Text] [Related]
37. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.
Rosenberg S; Verreault M; Schmitt C; Guegan J; Guehennec J; Levasseur C; Marie Y; Bielle F; Mokhtari K; Hoang-Xuan K; Ligon K; Sanson M; Delattre JY; Idbaih A
Neuro Oncol; 2017 Feb; 19(2):219-228. PubMed ID: 27571888
[TBL] [Abstract][Full Text] [Related]
38. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.
Di Tacchio M; Macas J; Weissenberger J; Sommer K; Bähr O; Steinbach JP; Senft C; Seifert V; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Scheel AH; Büttner R; Grauer OM; Schittenhelm J; Tabatabai G; Harter PN; Günther S; Devraj K; Plate KH; Reiss Y
Cancer Immunol Res; 2019 Dec; 7(12):1910-1927. PubMed ID: 31597643
[TBL] [Abstract][Full Text] [Related]
39. Establishment and validation of an immune-based prognostic score model in glioblastoma.
Qin Z; Zhang X; Chen Z; Liu N
Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
[TBL] [Abstract][Full Text] [Related]
40. Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner.
Bayik D; Zhou Y; Park C; Hong C; Vail D; Silver DJ; Lauko A; Roversi G; Watson DC; Lo A; Alban TJ; McGraw M; Sorensen M; Grabowski MM; Otvos B; Vogelbaum MA; Horbinski C; Kristensen BW; Khalil AM; Hwang TH; Ahluwalia MS; Cheng F; Lathia JD
Cancer Discov; 2020 Aug; 10(8):1210-1225. PubMed ID: 32300059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
